Inhibitor development in haemophilia B: an orphan disease in need of attention
- PMID: 17614818
- DOI: 10.1111/j.1365-2141.2007.06657.x
Inhibitor development in haemophilia B: an orphan disease in need of attention
Abstract
Factor IX (FIX) inhibitors develop in 1.5-3% of haemophilia B patients. Due to its low incidence compared with that in haemophilia A, few comparable data exist on host and treatment-related risk factors, and immunological processes associated with FIX inhibitor development. Moreover, the safety and efficacy of bypass therapy as well as the outcome predictors of successful inhibitor eradication have been poorly characterised. The lack of a useful evidence-based approach to the diagnosis and management of FIX inhibitors complicates their significant morbidity due to the frequency of allergic reactions that often herald antibody development. This review discusses what is currently known about the epidemiology, natural history and immunology of anti-FIX antibody development. It addresses several special considerations in the approach to the treatment of bleeding and inhibitor eradication. A case is made for moving forward with an integrated international collaboration for the further study of the nature and treatment of this problem.
Similar articles
-
Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).Haemophilia. 2009 Sep;15(5):1027-31. doi: 10.1111/j.1365-2516.2009.02039.x. Epub 2009 Jun 10. Haemophilia. 2009. PMID: 19515028
-
Development of anaphylactic shock in haemophilia B patients with inhibitors.Blood Coagul Fibrinolysis. 1998 Mar;9 Suppl 1:S125-8. Blood Coagul Fibrinolysis. 1998. PMID: 9819043 Clinical Trial.
-
Immune tolerance in haemophilia: the long journey to the fork in the road.Br J Haematol. 2012 Oct;159(2):123-34. doi: 10.1111/bjh.12028. Epub 2012 Aug 28. Br J Haematol. 2012. PMID: 22924753 Review.
-
Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.Thromb Haemost. 1999 Oct;82(4):1247-9. Thromb Haemost. 1999. PMID: 10544907
-
Immune tolerance: critical issues of factor dose, purity and treatment complications.Haemophilia. 2006 Dec;12 Suppl 6:81-5; discussion 85-6. doi: 10.1111/j.1365-2516.2006.01376.x. Haemophilia. 2006. PMID: 17123399 Review.
Cited by
-
Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex.Haematologica. 2012 Aug;97(8):1165-72. doi: 10.3324/haematol.2011.055699. Epub 2012 Apr 4. Haematologica. 2012. PMID: 22491732 Free PMC article.
-
Evaluation of transfusion-related complications along with estimation of inhibitors in patients with hemophilia: A pilot study from a single center.Asian J Transfus Sci. 2013 Jan;7(1):8-10. doi: 10.4103/0973-6247.106714. Asian J Transfus Sci. 2013. PMID: 23559756 Free PMC article.
-
Design and characterization of an APC-specific serpin for the treatment of hemophilia.Blood. 2017 Jan 5;129(1):105-113. doi: 10.1182/blood-2016-05-718635. Epub 2016 Oct 27. Blood. 2017. PMID: 27789479 Free PMC article.
-
Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice.EMBO Mol Med. 2013 Nov;5(11):1684-97. doi: 10.1002/emmm.201302857. Epub 2013 Sep 16. EMBO Mol Med. 2013. PMID: 24106222 Free PMC article.
-
Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B.Blood Adv. 2021 Jul 13;5(13):2732-2739. doi: 10.1182/bloodadvances.2020004085. Blood Adv. 2021. PMID: 34242387 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
